Drugs / DAO supplement
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06139744 | Nov 2023 → Aug 2024 | irritable bowel syndrome | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAO supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06139744 ↗ |
| Route | Oral | “taken orally” NCT06139744 ↗ |